Table 3.
Patient Characteristics: Pharmacokinetic
| Characteristic | Erlotinib Dose (mg per day) |
||
|---|---|---|---|
| 150 (n = 17) | 300 (n = 18) | Total (N = 35) | |
| Sex | |||
| Male | 8 | 8 | 16 |
| Female | 9 | 10 | 19 |
| Median age, years | 63 | 61 | 61 |
| Range | 50-78 | 40-75 | 40-78 |
| Histology | |||
| Adenocarcinoma | 6 | 10 | 16 |
| Squamous | 6 | 6 | 12 |
| Undifferentiated large cell | 1 | 1 | 2 |
| Other/not specified | 4 | 1 | 5 |
| ECOG PS | |||
| 0 | 2 | 1 | 3 |
| 1 | 15 | 17 | 32 |
| Prior radiotherapy | 10 | 11 | 21 |
| No. of prior chemotherapy regimens* | |||
| 1 | 13 | 10 | 23 |
| 2 | 3 | 7 | 10 |
| 3 | 1 | 1 | 2 |
| Smoking history | |||
| Median no. cigarettes per day | 18 | 15 | 15 |
| Range | 10-40 | 10-30 | 10-40 |
| Median no. years smoked | 44 | 44 | 44 |
| Range | 2-60 | 20-63 | 2-63 |
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.
*
Two patients who received three prior regimens were included in the analyses.